2
Clinical Trials associated with BCG for therapeutic use(Chengdu Institute of Biological Products)Nivolumab 或Nivolumab/ BMS-986205 单用或与膀胱内BCG联合治疗BCG无应答的高危非肌层浸润性膀胱癌受试者的II期、随机、开放性研究
[Translation] A phase II, randomized, open-label study of nivolumab or nivolumab/BMS-986205 alone or in combination with intravesical BCG in subjects with high-risk non-muscle invasive bladder cancer who are unresponsive to BCG
描述nivolumab 和 nivolumab+BMS-986205单药或与膀胱内BCG联合使用的安全性和耐受性。 表征nivolumab的免疫原性
[Translation] To describe the safety and tolerability of nivolumab and nivolumab + BMS-986205 alone or in combination with intravesical BCG. To characterize the immunogenicity of nivolumab
卡介苗膀胱灌注在预防中、高危非肌层浸润性膀胱癌术后复发的有效性、安全性的随机、对照、多中心临床试验
[Translation] A randomized, controlled, multicenter clinical trial on the effectiveness and safety of intravesical BCG in preventing postoperative recurrence of intermediate- and high-risk non-muscle invasive bladder cancer
以注射用盐酸表柔比星为对照,评价治疗用卡介苗用于预防中、高危非肌层浸润性膀胱癌术后复发的有效性和安全性。
[Translation] To evaluate the efficacy and safety of therapeutic BCG in preventing postoperative recurrence of intermediate- and high-risk non-muscle invasive bladder cancer, using epirubicin hydrochloride for injection as a control.
100 Clinical Results associated with BCG for therapeutic use(Chengdu Institute of Biological Products)
100 Translational Medicine associated with BCG for therapeutic use(Chengdu Institute of Biological Products)
100 Patents (Medical) associated with BCG for therapeutic use(Chengdu Institute of Biological Products)
100 Deals associated with BCG for therapeutic use(Chengdu Institute of Biological Products)